Screener
D&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ocular Therapeutix in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Ocular Therapeutix’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:28 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055256
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Stock-based compensation expense | 15,582 | 10,456 |
| Non-cash interest expense | 1,381 | 1,436 |
| Change in fair value of derivative liabilities | (1,455) | 978 |
| Depreciation and amortization expense | 1,283 | 981 |
| Loss on disposal of items of property and equipment | 4,866 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | 6,303 | 7,167 |
| Prepaid expenses and other current assets | (357) | 3,934 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Ocular Therapeutix's D&A?
- Ocular Therapeutix (OCUL) reported D&A of $1.28M in Q1 2026.
- How has Ocular Therapeutix's D&A changed year-over-year?
- Ocular Therapeutix's D&A increased by 30.8% year-over-year, from $981K to $1.28M.
- What is the long-term trend for Ocular Therapeutix's D&A?
- Over 4 years (2021 to 2025), Ocular Therapeutix's D&A has grown at a 15.6% compound annual growth rate (CAGR), from $2.42M to $4.32M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.
Ask your AI about Ocular Therapeutix's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude